Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 812
- Registration Number
- NCT05296798
- Locations
- 🇮🇹
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy
🇵🇱Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Poland
🇵🇹Hospital de S. Francisco Xavier; Unidade de Oncologia Medica, Lisboa, Portugal
A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 151
- Registration Number
- NCT05275010
- Locations
- 🇦🇺
CMAX Pty Ltd, Adelaide, South Australia, Australia
🇦🇺Q-Pharm Pty Ltd; Nucleus Network Brisbane Clinic, Herston, Queensland, Australia
🇳🇿New Zealand Clinical Research - Christchurch, Christchurch, New Zealand
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
- Conditions
- Interventions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT05271409
- Locations
- 🇦🇺
Royal Childrens Hospital; Childrens Neuroscience Centre, Parkville, Victoria, Australia
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic- Scottsdale, Scottsdale, Arizona, United States
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4
- Registration Number
- NCT05269667
- Locations
- 🇨🇦
Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada
🇮🇹Azienda Ospedaliera Sant'Andrea, Roma, Lazio, Italy
🇮🇹Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, Italy
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1300
- Registration Number
- NCT05269004
- Locations
- 🇦🇺
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇷🇺Sverdlovsk Regional Clinical Hospital 1, Yekaterinburg, Sverdlovsk, Russian Federation
🇺🇸Northwestern University, Chicago, Illinois, United States
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT05256134
- Locations
- 🇺🇸
Visionary Investigators Network - Neurology Aventura, Aventura, Florida, United States
🇺🇸Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States
🇺🇸Premiere Research Institute, West Palm Beach, Florida, United States
An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05251948
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou City, China
🇨🇳Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou City, China
🇨🇳The General Hospital of People?s Liberation Army (301 Hospital), Beijing City, China
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 250
- Registration Number
- NCT05240898
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 236
- Registration Number
- NCT05232825
- Locations
- 🇺🇸
Johns Hopkins Hospital; Neurology, Baltimore, Maryland, United States
🇺🇸Premier Neurology, Greenville, South Carolina, United States
🇺🇸UC Health Neurology, Dayton, Ohio, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 53
- Registration Number
- NCT05219513
- Locations
- 🇫🇷
CHRU Lille - Hôpital Claude Huriez; Service des Maladies du Sang, Lille, France
🇮🇹ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy
🇮🇹Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy